<DOC>
	<DOC>NCT02013791</DOC>
	<brief_summary>This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will participate in Stage 2 of this study.</brief_summary>
	<brief_title>Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Moderate to severe dry eye disease in both eyes Bestcorrected visual acuity (BCVA) of 20/100 or better in each eye Use of any cyclosporine preparations within 3 months Use of topical medications, other than artificial tears, in the eyes within 1 month Use of contact lenses in either eye within 1 month Stage 2 only: Participation in Stage 1 of this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>